In April 2023, two conflicting federal rulings were issued in relation to the availability of mifepristone, an abortion pill, in the United States. A federal judge in Texas invalidated the FDA's 23-year-old approval of mifepristone, while a judge in Washington state issued a ruling that contradicted the Texas decision and ordered the FDA to maintain the availability of mifepristone. These conflicting orders by two federal judges create a legal standoff that could potentially escalate to the Supreme Court.

This question will resolve positively if the US Supreme Court agrees to hear a case related to the conflicting federal rulings on mifepristone's availability by December 31, 2024. The case must specifically involve the rulings issued in Texas and Washington state in April 2023.

The question will resolve negatively if the Supreme Court declines to hear such a case or if there is no announcement regarding the acceptance of a case involving the conflicting federal rulings on mifepristone's availability by December 31, 2024.

Relevant media sources, including but not limited to, official Supreme Court announcements, credible news outlets, and legal journals, will be used to determine the resolution.